SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Millennium Pharmaceuticals, Inc. (MLNM)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: Icebrg6/4/2007 6:22:08 AM
   of 3044
 
Kosan (KOSN) reported today on a Phase 1 Clinical Trial of Tanespimycin (KOS-953) + Bortezomib in Relapsed Refractory Multiple Myeloma.

Message 23595929

Responses were observed across dose cohorts in bortezomib-naive, pretreated and refractory patients (refractory is defined as having no response to prior bortezomib or having progressed on or within 60 days of their last dose of a bortezomib-containing regimen). Response rate in multiple myeloma is measured primarily by the level of myeloma (M) protein in the patient's bone marrow. In those patients who received a dose of 1.0 or 1.3 mg/m2 of bortezomib, the overall response rate including complete, partial and minimal responses was 44% (18 out of 41 patients evaluable for response):

-- 8 out of 14 bortezomib-naive patients (57%);
-- 7 out of 16 bortezomib-pretreated patients (44%); and
-- 3 out of 11 bortezomib-refractory patients (27%).

In the bortezomib-refractory group, the following patients responded:

-- 1 patient with 4 prior regimens had a confirmed partial response after 2 cycles and continues in the trial for more than one year (cycle 23+; M-spike best decrease 96%);

-- 1 patient with 3 prior regimens had a confirmed partial response after 2 cycles and continues in the trial after more than 46 weeks (cycle 15+; urinary M-protein not measurable); and

-- 1 patient with 7 prior regimens had a confirmed partial response after 3 cycles and was in the trial for 23 weeks (completed 8 cycles; M-spike maximal decrease 89%) and was removed from study while still in partial response; 4 months later, the patient remains in partial response (total 39+ weeks).

These results look good and KOSN is about to start up a pivotal trial based on these results.

För MLNM who is on the lookout for partnering/munching opportunities, KOSN should look quite tempting at its current market cap of around 260 mUSD (no long-term debt).

Erik
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News